Why Shares of Zogenix Fell 26% in September презентация

Nasdaq Biotechnology ETF (NASDAQ: IBB) fell 9% during the month.

despite releasing good clinical news.

company’s experimental once a month Schizophrenia medication, was released in September.
Results look good enough to start phase 3 testing, but the company is holding off until it finds a partner, which may be the reason that investors dumped the shares.
The company estimates trials will begin in Q1 2016.
Peak sales are estimated to be around $250 million annually.

as a treatment for Dravet Syndrome, which is an orphan disease that causes seizures that do not respond to standard treatments.
ZX008 has received orphan drug designation in the U.S. & Europe, and peak sales estimates are around $200 million.
Phase 3 studies for ZX008 should start in the fourth quarter of 2015.

The company raised $98 million in an August common stock offering, so it appears to be well capitalized.

Zogenix remains very speculative, so I’m content to stay away until we see good phase 3 data for either ZX008 or Relday.